

# Alison H H Thomson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3522812/publications.pdf>

Version: 2024-02-01

92  
papers

3,663  
citations

172207

29  
h-index

133063

59  
g-index

93  
all docs

93  
docs citations

93  
times ranked

3197  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. <i>Critical Care Medicine</i> , 2000, 28, 632-637.	0.4	615
2	Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. <i>Clinical Cancer Research</i> , 1999, 5, 83-94.	3.2	588
3	Cost-Effectiveness of Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 10-17.	1.0	189
4	Bayesian Parameter Estimation and Population Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 1992, 22, 447-467.	1.6	133
5	Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 1050-1057.	1.3	124
6	External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1068-1080.	1.1	92
7	Pharmacokinetics and dose requirements of vancomycin in neonates. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 1999, 81, F221-F227.	1.4	87
8	Value of theophylline treatment in patients handicapped by chronic obstructive lung disease.. <i>Thorax</i> , 1993, 48, 227-232.	2.7	82
9	Predictors of new onset diabetes after renal transplantation. <i>Clinical Transplantation</i> , 2007, 21, 136-143.	0.8	82
10	Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours. <i>British Journal of Cancer</i> , 1999, 81, 99-107.	2.9	76
11	Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 713-718.	1.3	67
12	A population model of epirubicin pharmacokinetics and application to dosage guidelines. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 34-40.	1.1	65
13	Population Pharmacokinetics of Tobramycin in Patients With and Without Cystic Fibrosis. <i>Clinical Pharmacokinetics</i> , 2013, 52, 289-301.	1.6	59
14	Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations. <i>Clinical Pharmacokinetics</i> , 2019, 58, 767-780.	1.6	57
15	Population Pharmacokinetics of Caffeine in Neonates and Young Infants. <i>Therapeutic Drug Monitoring</i> , 1996, 18, 245-253.	1.0	55
16	Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 367-377.	1.1	53
17	Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2754-2759.	1.3	53
18	Pharmacokinetic Optimisation of Anticonvulsant Therapy. <i>Clinical Pharmacokinetics</i> , 1992, 23, 216-230.	1.6	52

#	ARTICLE	IF	CITATIONS
19	Population Pharmacokinetics of Gentamicin in Neonates. <i>Developmental Pharmacology and Therapeutics</i> , 1988, 11, 173-179.	0.2	50
20	Estimation of gentamicin clearance and volume of distribution in neonates and young children.. <i>British Journal of Clinical Pharmacology</i> , 1984, 18, 685-692.	1.1	46
21	The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1987, 15, 101-115.	0.6	42
22	Variability in hydrocortisone plasma and saliva pharmacokinetics following intravenous and oral administration to Patients with adrenal insufficiency. <i>Clinical Endocrinology</i> , 2007, 66, 789-796.	1.2	42
23	Evaluation and Comparison of Simple Multiple Model, Richer Data Multiple Model, and Sequential Interacting Multiple Model (IMM) Bayesian Analyses of Gentamicin and Vancomycin Data Collected From Patients Undergoing Cardiothoracic Surgery. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 67-74.	1.0	41
24	Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 181-187.	1.3	40
25	A clinically significant interaction between ciprofloxacin and theophylline. <i>European Journal of Clinical Pharmacology</i> , 1987, 33, 435-436.	0.8	39
26	Case report: severe mercuric sulphate poisoning treated with 2,3-dimercaptopropane-1-sulphonate and haemodiafiltration. <i>Critical Care</i> , 2003, 7, R1.	2.5	39
27	Population pharmacokinetics of gentamicin in patients with cancer. <i>British Journal of Clinical Pharmacology</i> , 1998, 46, 229-236.	1.1	35
28	Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 164-176.	1.1	34
29	Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2128-2138.	1.3	33
30	Clinical pharmacokinetics: a comprehensive system for therapeutic drug monitoring and prescribing.. <i>BMJ: British Medical Journal</i> , 1984, 288, 541-545.	2.4	30
31	Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 882-890.	1.3	28
32	Pharmacokinetic profiles of epidural bupivacaine and ropivacaine following single-shot and continuous epidural use in young infants. <i>Paediatric Anaesthesia</i> , 2012, 22, 430-437.	0.6	27
33	Continuous infusion of vancomycin in neonates. <i>Archives of Disease in Childhood</i> , 2013, 98, 478-479.	1.0	27
34	Therapeutic drug monitoring in the past 40 years of the <i>Journal of Antimicrobial Chemotherapy</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3330-3332.	1.3	27
35	The pharmacokinetics of Râ€•and Sâ€•ocainide in patients with acute ventricular arrhythmias.. <i>British Journal of Clinical Pharmacology</i> , 1986, 21, 149-154.	1.1	26
36	Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 38, 566-570.	1.1	23

#	ARTICLE	IF	CITATIONS
37	Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1338-1347.	1.3	23
38	Lisinopril population pharmacokinetics in elderly and renal disease patients with hypertension.. <i>British Journal of Clinical Pharmacology</i> , 1989, 27, 57-65.	1.1	21
39	Evaluation of a Bayesian Approach to the Pharmacokinetic Interpretation of Cyclosporin Concentrations in Renal Allograft Recipients. <i>Therapeutic Drug Monitoring</i> , 1994, 16, 160-165.	1.0	20
40	Development of a LC-MS method for simultaneous determination of amoxicillin and metronidazole in human serum using hydrophilic interaction chromatography (HILIC). <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1089, 78-83.	1.2	20
41	Drug Clearance in Neonates: A Combination of Population Pharmacokinetic Modelling and Machine Learning Approaches to Improve Individual Prediction. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1435-1448.	1.6	20
42	Dosing regimens of oral ciprofloxacin for children with severe malnutrition: a population pharmacokinetic study with Monte Carlo simulation. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2336-2345.	1.3	19
43	Population pharmacokinetics of intramuscular gentamicin administered to young infants with suspected severe sepsis in Kenya. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 25-31.	1.1	18
44	Pharmacokinetics and tissue penetration of vancomycin continuous infusion as prophylaxis for vascular surgery. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2624-2627.	1.3	18
45	Research is a step into the unknown™: an exploration of pharmacists'™ perceptions of factors impacting on research participation in the NHS. <i>BMJ Open</i> , 2015, 5, e009180.	0.8	18
46	Evaluation of Nonlinear Regression with Extended Least Squares: Simulation Study. <i>Journal of Pharmaceutical Sciences</i> , 1985, 74, 1327-1330.	1.6	16
47	Population Pharmacokinetics of Rectal Theophylline in Neonates. <i>Therapeutic Drug Monitoring</i> , 1991, 13, 195-200.	1.0	16
48	Population pharmacokinetics of a single daily intramuscular dose of gentamicin in children with severe malnutrition. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 681-689.	1.3	16
49	Characterisation and evaluation of UK websites on attention deficit hyperactivity disorder. <i>Archives of Disease in Childhood</i> , 2008, 93, 695-700.	1.0	16
50	Evaluation of Six Gentamicin Nomograms Using a Bayesian Parameter Estimation Program. <i>Therapeutic Drug Monitoring</i> , 1990, 12, 258-263.	1.0	15
51	Gerontokinetics-a reappraisal [see comments]. <i>British Journal of Clinical Pharmacology</i> , 1992, 33, 1-2.	1.1	15
52	Population Pharmacokinetics of Aminoglycoside Antibiotics in Patients With Cystic Fibrosis. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 281.	1.0	15
53	Development of guidelines for gentamicin dosing. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 38, 885-893.	1.3	14
54	A survey of extraction techniques for drugs of abuse in urine. <i>Forensic Science International</i> , 2001, 119, 23-27.	1.3	14

#	ARTICLE	IF	CITATIONS
55	Assessment of the validity of a population pharmacokinetic model for epirubicin. <i>British Journal of Clinical Pharmacology</i> , 2006, 62, 47-55.	1.1	13
56	A review of vancomycin therapeutic drug monitoring recommendations in Scotland. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 1398-1399.	1.3	12
57	Population Pharmacokinetics of Lisinopril in Hypertensive Patients. <i>Gerontology</i> , 1987, 33, 17-23.	1.4	11
58	Barriers to the safe and effective use of intravenous gentamicin and vancomycin in Scottish hospitals, and strategies for quality improvement. <i>European Journal of Hospital Pharmacy</i> , 2015, 22, 32-37.	0.5	11
59	Gentamicin and Vancomycin Removal by Continuous Venovenous Hemofiltration. <i>DICP: the Annals of Pharmacotherapy</i> , 1991, 25, 127-129.	0.2	10
60	Designing simple PK-PD studies in children. <i>Paediatric Anaesthesia</i> , 2011, 21, 190-196.	0.6	10
61	Influence of Genotype on Warfarin Maintenance Dose Predictions Produced Using a Bayesian Dose Individualization Tool. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 677-683.	1.0	10
62	The value of therapeutic drug monitoring to the practising physician—a hypothesis needing sensible application.. <i>British Journal of Clinical Pharmacology</i> , 1989, 28, 619-620.	1.1	9
63	Flucytosine dose requirements in a patient receiving continuous veno-venous haemofiltration. <i>Intensive Care Medicine</i> , 2002, 28, 999-999.	3.9	9
64	Professional development beyond foundation training: a study of pharmacists working in Scotland. <i>International Journal of Pharmacy Practice</i> , 2020, 28, 165-172.	0.3	9
65	Prediction of Intravenous Cyclosporine Area Under the Concentration-Time Curve After Allogeneic Stem Cell Transplantation. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 353-358.	1.0	8
66	Method for the Quantification of Diamorphine and its Metabolites in Pediatric Plasma Samples by Liquid Chromatography-Tandem Mass Spectrometry. <i>Journal of Analytical Toxicology</i> , 2010, 34, 177-195.	1.7	8
67	Changes in Lignocaine Disposition during Long-Term Infusion in Patients with Acute Ventricular Arrhythmias. <i>Therapeutic Drug Monitoring</i> , 1987, 9, 283-291.	1.0	7
68	Do Vancomycin Pharmacokinetics Differ Between Obese and Non-obese Patients? Comparison of a General-Purpose and Four Obesity-Specific Pharmacokinetic Models. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 126-130.	1.0	7
69	The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets. <i>European Journal of Clinical Pharmacology</i> , 1988, 34, 47-50.	0.8	6
70	Pharmacokinetic/pharmacodynamic analysis of weight- and height-scaled tobramycin dosage regimens for patients with cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2311-2317.	1.3	6
71	Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling. <i>British Journal of Clinical Pharmacology</i> , 2004, 57, 764-772.	1.1	5
72	Hepatocellular Damage Following Therapeutic Intravenous Iron Sucrose Infusion in a Child. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 405-408.	1.0	5

#	ARTICLE	IF	CITATIONS
73	An Audit of Therapeutic Drug Monitoring Service Provision by Laboratories Participating in an External Quality Assessment Scheme. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 248-252.	1.0	5
74	Disopyramide in acute myocardial infarction: Problems with changing pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , 1986, 30, 345-347.	0.8	4
75	External quality assessment of laboratory performance in analysis of toxicological cases. <i>Forensic Science International</i> , 2001, 121, 27-32.	1.3	4
76	Development and evaluation of a national gentamicin and vancomycin quality improvement programme. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1998-2003.	1.3	3
77	Bayesian Estimation of Streptomycin Pharmacokinetics. <i>Therapeutic Drug Monitoring</i> , 1992, 14, 522-524.	1.0	2
78	Scoring and Performance of Analysis and Interpretation of Toxicologic Cases Assessed by External Quality Assurance. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 156-158.	1.0	2
79	Population Pharmacokinetics Of Teicoplanin In Outpatient Home Parenteral Antibiotic Therapy (OHPAT). <i>Therapeutic Drug Monitoring</i> , 2005, 27, 227.	1.0	2
80	Evaluation of antipsychotic information on UK schizophrenia websites. <i>The Psychiatrist</i> , 2010, 34, 422-426.	0.3	2
81	Evaluation of a New Seralyzer Assay for Carbamazepine. <i>Therapeutic Drug Monitoring</i> , 1988, 10, 355-358.	1.0	1
82	Aminoglycosides: old friend   new foe?. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 411-412.	0.3	1
83	Population pharmacokinetic evaluation and optimization of amikacin dosage regimens for the management of mycobacterial infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2933-2940.	1.3	1
84	Genetic Algorithms as a Tool for Dosing Guideline Optimization: Application to Intermittent Infusion Dosing for Vancomycin in Adults. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 294-302.	1.3	1
85	Evaluation of amoxicillin, metronidazole and gentamicin dosage regimens for use in antibiotic prophylaxis in colorectal surgery. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3212-3219.	1.3	1
86	Theophylline toxicity following coadministration of viloxazine. <i>Therapeutic Drug Monitoring</i> , 1988, 10, 359-60.	1.0	1
87	BAYESIAN FEEDBACK METHODS FOR OPTIMISING THERAPY. <i>Clinical Neuropharmacology</i> , 1992, 15, 245A-246A.	0.2	0
88	Population Pharmacokinetic Modelling Of Gentamicin And Vancomycin In Patients With Unstable Renal Function Following Cardiac Surgery. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 227.	1.0	0
89	Bioavailability study of a concentrated suspension of phenytoin in healthy volunteers. <i>International Journal of Pharmacy Practice</i> , 2011, 1, 216-219.	0.3	0
90	Pharmacokinetics and dose requirements of disopyramide in neonates and children. <i>International Journal of Pharmacy Practice</i> , 2011, 2, 58-59.	0.3	0

#	ARTICLE	IF	CITATIONS
91	Cyclosporine dose Intensity Is a Critical Determinant of Outcome after a T Cell Depleted Reduced Intensity Allograft.. Blood, 2008, 112, 1153-1153.	0.6	0
92	Individualization of drug dosage--past, present and future. Medizinische Monatsschrift Fur Pharmazeuten, 2003, 26, 150-2.	0.1	0